AstraZeneca PLC Bond Offering
On September 1, 2026, AstraZeneca PLC announced a significant bond offering through its wholly-owned subsidiary, AstraZeneca Finance LLC. The offering, totaling β¬2.55 billion, involves four series of notes admitted to trading on the Main Market of the London Stock Exchange. These include β¬700 million in 3.402% notes due March 1, 2030; β¬600 million in 3.652% notes due September 1, 2032; β¬500 million in 3.923% notes due September 1, 2035; and β¬750 million in 4.169% notes due September 1, 2038. The company has provided access to the final terms for each series and the base prospectus dated June 9, 2026, for further details. This debt financing is targeted at eligible counterparties and professional clients only and is not intended for retail investors in the EEA or the UK.